Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma.
Taruba RaisAfsheen KhanRumaisa RiazPublished in: Rare tumors (2023)
Multiple myeloma is the second most common plasma cell malignancy, characterized by uncontrolled proliferation of plasma cells within the bone marrow. ELREXFIO™ (elranatamab-bcmm) is a recently FDA-approved drug for relapsed and refractory multiple myeloma. The progression of multiple myeloma involves interactions with various bone marrow cell types, and targeting this microenvironment has shown promising results in inhibiting its growth and osteolysis. ELREXFIO, a bispecific antibody targeting CD3 and BCMA, activates cytotoxic T-lymphocyte responses against BCMA-expressing myeloma cells. Clinical trials, such as MagnetisMM-3, demonstrated significant response rates and long-term tolerability. Its approval offers hope to multiple myeloma patients, especially those with relapsed or refractory cases, as innovative therapies like ELREXFIO continue to improve outcomes in this challenging malignancy.
Keyphrases
- multiple myeloma
- bone marrow
- induced apoptosis
- clinical trial
- mesenchymal stem cells
- cell cycle arrest
- end stage renal disease
- single cell
- signaling pathway
- ejection fraction
- stem cells
- cancer therapy
- cell therapy
- endoplasmic reticulum stress
- chronic kidney disease
- randomized controlled trial
- cell death
- peritoneal dialysis
- oxidative stress
- cell proliferation
- prognostic factors
- type diabetes
- drug administration
- open label
- drug delivery
- adipose tissue
- combination therapy
- phase ii
- hodgkin lymphoma